Ochronosis

Last updated
Ochronosis
Homogentisic acid.svg
Homogentisic acid
Specialty Endocrinology   OOjs UI icon edit-ltr-progressive.svg
Ocher pigment, after which the condition was named, due to the similar color of affected tissue Hellocker- Pigment.JPG
Ocher pigment, after which the condition was named, due to the similar color of affected tissue

Ochronosis is a syndrome caused by the accumulation of homogentisic acid in connective tissues. The condition was named after the yellowish (ocher-like) discoloration of the tissue seen on microscopic examination. Macroscopically, though, the affected tissues appear bluish-grey because of a light-scattering phenomenon known as the Tyndall effect. The condition is most often associated with alkaptonuria, but can occur from exogenous administration of phenol complexes such as hydroquinone. It was first described by Rudolf Virchow in 1865. [1]

Contents

Types

The two types of ochronosis are endogenous and exogenous. The endogenous variety is an autosomal-recessive disease, known as alkaptonuria, that is caused by a lack of homogentisate oxidase enzyme. [2] Exogenous ochronosis is an avoidable dermatitis that can be caused by the topical application of compounds such as hydroquinone or phenols. [2] It was first seen in 1912, when a patient who used phenol on a leg ulcer was found by Beddard and Plumtre to have this condition. [3] Hydroquinone-induced exogenous ochronosis was found in 1975 by Findlay, who observed the condition in patients who used skin lightening creams containing the compound. [4]

The three clinical stages of exogenous ochronosis are: [5]

  1. Erythema and mild hyperpigmentation
  2. Hyperpigmentation and "caviar-like" lesions
  3. Papulonodular lesions

Signs and symptoms

Symptoms of exogenous ochronosis include: [7]

  1. Yellow-brown, banana-shaped fibers
  2. Caviar-like papules
  3. Brown-grey or blue-black hyperpigmentation

Most of the lesions are seen on areas of the body that get the most sun. [2]

Causes

Exogenous ochronosis can be caused from long-term use of certain "skin-lightening" products, even if the hydroquinone is in amounts as small as 2%. [2] Skin-lightening products are still prevalent in many parts of the world. [8] This may be due to aesthetic or social-standing reasons, in areas where a lighter skin tone is considered to be a sign of wealth or beauty. [8] Also, skin-lightening creams containing compounds such as hydroquinone are commonly used to help with hyperpigmentation disorders such as melasma. [9]

Hydroquinone is the compound most frequently used in skin-whitening products. Due to concerns about its side effects, it was almost banned by the FDA in 2006, as medical issues of carcinogenicity and reports of disfiguring ochronosis existed. [10] In the European Union hydroquinone has been banned in cosmetic creams since 2000. [11]

Long-term use of creams containing this compound may lead to exogenous ochronotic lesions. The duration of use is directly proportional to the risk of developing the condition, with most cases occurring after years of use. [2] Around 10–15 million skin lightening products are sold annually, with Japan being the major buyer. [12]

Pathophysiology

Ochronosis occurs because of deposition of phenols (such as homogentisic acid and hydroquinone) as plaques in the matrix of cartilage. The pigments can also be incorporated into collagen and elastin fibers. In the skin, the pigment alters the structure of the fibers, causing enlargement and curling. The embedded pigments also form crosslinks with pigment depositions in adjacent fibers, stabilizing and reducing the elastic recoil of the fibers. This results in hardening of elastic structures, increasing their rigidity and brittleness. Once ruptured, the exposed pigments cause a foreign body reaction and inflammation. This pigment deposition also invokes deposition of hydroxyapatite, the mineral responsible for bone calcification, further hardening the connective tissue. The pigment can also be excreted by glandular cells in apocrine and ceruminous sweat glands, as well as breast and prostate tissue. This results in darkly pigmented sweat and breast milk. Excretion of the pigment is only found in endogenous ochronosis and should not occur from topical phenols.[ citation needed ]

Pathophysiology of alcaptonuria is due to the absence of functional homogentisate dioxygenase in the liver Inborn errors of metabolism of phenylalanine and tyrosine.svg
Pathophysiology of alcaptonuria is due to the absence of functional homogentisate dioxygenase in the liver

Diagnosis

The diagnosis is often made as an incidental finding intraoperatively. Cartilage exposed to the air turns dark gray or black within minutes.[ citation needed ]

Treatment

Treatment is predominantly preventive. Avoidance of topical phenols and diets low in tyrosine may help.[ citation needed ] Replacement and repair of damaged tissue is also possible.

Hydroquinone-induced exogenous ochronosis is an avoidable dermatosis that is exceedingly difficult to treat. However, some studies show that treatment may be possible with a Q-switched alexandrite (755 nm) laser. [13]

Individuals with this disorder are recommended to stop using hydroquinone-containing compounds. [2] Awareness of this is important, as dermatologists may think the symptoms a patient is exhibiting are a melasma, and prescribe a hydroquinone-containing cream. [13]

See also

Related Research Articles

<span class="mw-page-title-main">Alkaptonuria</span> Medical condition

Alkaptonuria is a rare inherited genetic disease which is caused by a mutation in the HGD gene for the enzyme homogentisate 1,2-dioxygenase ; if a person inherits an abnormal copy from both parents, the body accumulates an intermediate substance called homogentisic acid in the blood and tissues. Homogentisic acid and its oxidized form alkapton are excreted in the urine, giving it an unusually dark color. The accumulating homogentisic acid causes damage to cartilage and heart valves, as well as precipitating as kidney stones and stones in other organs. Symptoms usually develop in people over 30 years old, although the dark discoloration of the urine is present from birth.

<span class="mw-page-title-main">Nevus</span> Mole or birthmark; visible, circumscribed, chronic skin lesion

Nevus is a nonspecific medical term for a visible, circumscribed, chronic lesion of the skin or mucosa. The term originates from nævus, which is Latin for "birthmark"; however, a nevus can be either congenital or acquired. Common terms, including mole, birthmark, and beauty mark, are used to describe nevi, but these terms do not distinguish specific types of nevi from one another.

<span class="mw-page-title-main">Calcinosis cutis</span> Medical condition in which calcium deposits form in the skin

Calcinosis cutis is an uncommon condition marked by calcium buildup in the skin and subcutaneous tissues. Calcinosis cutis can range in intensity from little nodules in one area of the body to huge, crippling lesions affecting a vast portion of the body. Five kinds of the condition are typically distinguished: calciphylaxis, idiopathic calcification, iatrogenic calcification, dystrophic calcification, and metastatic calcification.

<span class="mw-page-title-main">Hyperpigmentation</span> Darkening of an area of skin or nails due to increased melanin

Hyperpigmentation is the darkening of an area of skin or nails caused by increased melanin.

<span class="mw-page-title-main">Periorbital dark circles</span> Dark blemishes around the eyes

Periorbital dark circles are dark blemishes around the eyes. There are many cause of this symptom, including heredity and bruising.

<span class="mw-page-title-main">Melasma</span> Medical condition

Melasma is a tan or dark skin discoloration. Melasma is thought to be caused by sun exposure, genetic predisposition, hormone changes, and skin irritation. Although it can affect anyone, it is particularly common in women, especially pregnant women and those who are taking oral or patch contraceptives or hormone replacement therapy medications.

<span class="mw-page-title-main">Hydroquinone</span> Chemical compound

Hydroquinone, also known as benzene-1,4-diol or quinol, is an aromatic organic compound that is a type of phenol, a derivative of benzene, having the chemical formula C6H4(OH)2. It has two hydroxyl groups bonded to a benzene ring in a para position. It is a white granular solid. Substituted derivatives of this parent compound are also referred to as hydroquinones. The name "hydroquinone" was coined by Friedrich Wöhler in 1843.

<span class="mw-page-title-main">Azelaic acid</span> Organic chemical compound

Azelaic acid (AzA) is an organic compound with the formula HOOC(CH2)7COOH. This saturated dicarboxylic acid exists as a white powder. It is found in wheat, rye, and barley. It is a precursor to diverse industrial products including polymers and plasticizers, as well as being a component of a number of hair and skin conditioners. AzA inhibits tyrosinase.

<span class="mw-page-title-main">Lentigo</span> Small pigment spots on skin

A lentigo is a small pigmented spot on the skin with a clearly defined edge, surrounded by normal-appearing skin. It is a harmless (benign) hyperplasia of melanocytes which is linear in its spread. This means the hyperplasia of melanocytes is restricted to the cell layer directly above the basement membrane of the epidermis where melanocytes normally reside. This is in contrast to the "nests" of multi-layer melanocytes found in moles. Because of this characteristic feature, the adjective "lentiginous" is used to describe other skin lesions that similarly proliferate linearly within the basal cell layer.

<span class="mw-page-title-main">Cysteamine</span> Chemical compound

Cysteamine is an organosulfur compound with the formula HSCH2CH2NH2. A white, water-soluble solid, it contains both an amine and a thiol functional groups. It is often used as salts of the ammonium derivative [HSCH2CH2NH3]+ including the hydrochloride, phosphocysteamine, and the bitartrate.The intermediate pantetheine is broken down into cysteamine and pantothenic acid.

<span class="mw-page-title-main">Skin whitening</span> Practice of using chemical substances to lighten the skin

Skin whitening, also known as skin lightening and skin bleaching, is the practice of using chemical substances in an attempt to lighten the skin or provide an even skin color by reducing the melanin concentration in the skin. Several chemicals have been shown to be effective in skin whitening, while some have proven to be toxic or have questionable safety profiles. This includes mercury compounds which may cause neurological problems and kidney problems.

<span class="mw-page-title-main">Arbutin</span> Glycoside

β-arbutin, also known by its International Nomenclature of Cosmetic Ingredients (INCI) name, arbutin, is a glycosylated derivative of hydroquinone. β-Arbutin is naturally present in the leaves and bark of a variety of plants, notably the bearberry plant, Arctostaphylos uva-ursi. Utilized as a biosynthetic active ingredient in topical treatments for skin lightening, β-arbutin is aimed at addressing hyperpigmentation issues. Its mechanism of action involves inhibiting the activity of tyrosinase, an essential enzyme for melanin synthesis in the human skin, thereby leading to a reduction in hyperpigmentation. It is important to distinguish β-arbutin from its structurally similar stereoisomer, α-arbutin, which exhibits similar effects in clinical applications.

Depigmentation is the lightening of the skin or loss of pigment. Depigmentation of the skin can be caused by a number of local and systemic conditions. The pigment loss can be partial or complete. It can be temporary or permanent.

Esoterica is an over-the-counter topical ointment applied to the skin for the purpose of lightening freckles, age spots, chloasma, melasma, and other skin discolorations due to a benign localized increase in the production of melanin. Esoterica may have other appropriate medical uses as determined by a physician.

Pigmentation disorders are disturbances of human skin color. There may be a loss or reduction, which may be related to loss of melanocytes or the inability of melanocytes to produce melanin or transport melanosomes correctly.

Photorejuvenation is a skin treatment that uses lasers, intense pulsed light, or photodynamic therapy to treat skin conditions and remove effects of photoaging such as wrinkles, spots, and textures. The process induces controlled wounds to the skin. This prompts the skin to heal itself, by creating new cells. This process—to a certain extent—removes the signs of photoaging. The technique was invented by Thomas L Roberts, III using CO2 lasers in the 1990s. Observed complications have included scarring, hyperpigmentation, acne, and herpes.

Kyrle disease is identified as a form of an acquired perforating disease. Other major perforating diseases are elastosis perforans serpiginosa and reactive perforating collagenosis. Recently, however, there is a controversy on categorizing Kyrle disease with perforating dermatosis or a subtype of acquired perforating collagenosis.

Postinflammatory hypopigmentation is a cutaneous condition characterized by decreased pigment in the skin following inflammation of the skin.

Oral pigmentation is asymptomatic and does not usually cause any alteration to the texture or thickness of the affected area. The colour can be uniform or speckled and can appear solitary or as multiple lesions. Depending on the site, depth, and quantity of pigment, the appearance can vary considerably.

α-Arbutin Glycoside

α-arbutin, is a glycosylated hydroquinone, and an anomer of the naturally occurring arbutin. α-Arbutin is used in the cosmetic and pharmaceutical industries for its skin lightening effects, treatment of hyperpigmentation, and as a safer alternative to hydroquinone.

References

  1. 1 2 Findlay GH, et al. Ochronosis. Clinics in Dermatology 1989;7:28–35
  2. 1 2 3 4 5 6 Charlín, R., Barcaui, C. B., Kac, B. K., Soares, D. B., Rabello-Fonseca, R. and Azulay-Abulafia, L. (2008), Hydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopy. International Journal of Dermatology, 47: 19–23. doi : 10.1111/j.1365-4632.2007.03351.x
  3. Beddard AP, Plumtre CM. "A further note on ochronosis associated with carboluria". Q S Med 1912; 5: 505–507.
  4. FINDLAY, G., MORRISON, J. and SIMSON, I. (1975), Exogenous ochronosis and pigmented colloid milium from hydroquinone bleaching creams. British Journal of Dermatology, 93: 613–622. doi : 10.1111/j.1365-2133.1975.tb05110.x
  5. Dogliotte M, Leibowitz M. "Granulomatous ochronosis – a cosmetic- induced skin disorder in blacks". S Afr Med J 1979; 56: 757–760.
  6. Linder, Moritz; Bertelmann, Thomas (2014). "On the ocular findings in ochronosis: a systematic review of the literature". BMC Ophthalmology. 14: 12–19. doi: 10.1186/1471-2415-14-12 . PMC   3915032 . PMID   24479547.
  7. Olumide, Y. M., Akinkugbe, A. O., Altraide, D., Mohammed, T., Ahamefule, N., Ayanlowo, S., Onyekonwu, C. and Essen, N. (2008), Complications of chronic use of skin lightening cosmetics. International Journal of Dermatology, 47: 344–353. doi : 10.1111/j.1365-4632.2008.02719.x
  8. 1 2 Joan Baxter (18 April 2000). "BBC News – AFRICA – The heavy cost of light skin". BBC.co.uk. Retrieved 9 January 2017.
  9. Rajaratnam R, Halpern J, Salim A, Emmett C. Interventions for melasma. Cochrane Database of Systematic Reviews 2010, Issue 7. Art. No.: CD003583. doi : 10.1002/14651858.CD003583.pub2.
  10. Toombs, E. L. (2007), Hydroquinone – what is it's[ sic ] future?. Dermatologic Therapy, 20: 149–156. doi : 10.1111/j.1529-8019.2007.00128.x
  11. "Skin lightening products – The Facts About – CTPA". TheFactsAbout.co.uk. Retrieved 9 January 2017.
  12. Leah Armstrong. "Global skin lightening market predicted to reach $10 billion by 2015 – WHITERskin". WhiterSkin.info. Archived from the original on 26 January 2017. Retrieved 9 January 2017.
  13. 1 2 Bellew, S. G. and Alster, T. S. (2004), Treatment of Exogenous Ochronosis With a Q-Switched Alexandrite (755 nm) Laser. Dermatologic Surgery, 30: 555–558. doi : 10.1111/j.1524-4725.2004.30177.x